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The issues of antivenom stability and distribution, and the training of health staff in the
correct use of antivenoms in Latin America were discussed in a workshop held at Instituto
Clodomiro Picado, Costa Rica, in September 16–19, 2008, under the auspices of the
program CYTED. Participants from public antivenom production laboratories of the region,
together with representatives of the Ministries of Health, from Argentina, Paraguay, Brazil,
Bolivia, Peru´, Ecuador, Colombia, Venezuela, Panama´, Costa Rica and Nicaragua partici-
pated in the event. Technical advances in the study of antivenom stability and in the design
of novel formulations aimed at generating products of higher stability were presented. In
addition, antivenom acquisition and distribution systems in every country were presented
and discussed, together with novel tools that could be useful for improving antivenom
distribution, such as the software SIGEpi, developed by the Pan American Health Orga-
nization. The issue of the cold chain, as well as the most frequent causes of misuse of
antivenoms in the region, were also analyzed. Finally, the experiences of training programs
for health staff on the correct use of antivenoms in snakebite envenomation treatment in
Latin America were presented. It was concluded that, in addition to the fostering of
antivenom production and quality control, renewed efforts should be implemented at
improving the stability, distribution and correct use of antivenoms in the region.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Snakebite envenomations constitute a signiﬁcant public
health problem in Latin America (Fan and Cardoso, 1995;
Gutie´rrez, 1995; Chippaux, 1998; Warrell, 2004; Kasturir-
atne et al., 2008). Antivenoms, the only validated treatment
for these envenomations, are produced in the region by
a heterogeneous universe of manufacturers which includes
laboratories predominantly belonging to public institutions
and others located in the private realm (Gutie´rrez et al.,
2007). Some countries and subregions in Latin America are: þ506 22920485.
rrez).
. All rights reserved.self-sufﬁcient in terms of antivenom supply, whereas
others are not. A regional project, supported by the orga-
nization CYTED (‘Ciencia y Tecnologı´a para el Desarrollo’),
started in 2006 with the aim of strengthening the endog-
enous capacity of public institutions in the region to
produce and control antivenoms. This network, which
includes laboratories and groups from 10 countries, has
a research component, as well as a capacity-building
component based on training exchange activities and
organization of annual workshops. Technical workshops on
antivenom production and quality control were organized
in 2006 and 2007 at Instituto Butantan (Brazil) and Insti-
tuto Clodomiro Picado (Costa Rica), respectively (Gutie´rrez
et al., 2007).
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snakebite envenomations involves other issues in addition
to the production and quality control of these immuno-
biologicals. These issues, often neglected in the analyses of
this subject, include the stability and distribution of anti-
venoms to the regions where they are going to be used, as
well as the training of the health staff in the correct use of
these drugs. This report presents the discussions and
conclusions of a workshop on the stability, distribution and
training in the use of antivenoms in Latin America, which
was held at Instituto Clodomiro Picado, Costa Rica in
September 16–19, 2008.
2. Stability of antivenoms and the cold chain
Stability studies of liquid antivenoms manufactured in
Costa Rica, Brazil, Peru and Colombia were presented.
These studies conﬁrmed the stability of various liquid
preparations stored for three years at 5 3 C. Since
different types of antivenoms, i.e. whole IgG and F(ab0)2
antivenoms, are manufactured by different laboratories,
the need to have stability studies by eachmanufacturer and
product formulation was emphasized. Two issues that
remain open for investigation are (a) what is the actual
shelf-life for liquid antivenom preparations?, and (b) what
is the effect on antivenom stability of short-term inter-
ruptions in the cold chain during the storage of these
products?. Preliminary evidence was presented supporting
the contention that the shelf-life of liquid preparations
stored at 5 3 C may be higher than three years, an issue
that requires further investigation. This is particularly
important in the case of antivenoms for envenomations
that occur infrequently, such as those induced by Lachesis
sp. and Micrurus sp. In these cases, it is common that
antivenoms are not used at the time of expiry; since these
antivenoms are precious medicines, difﬁcult to produce
and scarce, the possibility of extending their shelf-life is
very important and needs to be documented. A similar
situation occurs with freeze-dried antivenoms, whose
shelf-life has been estimated as being ﬁve years (Theakston
et al., 2003). There is circumstantial evidence indicating
that there shelf-life is likely to be more prolonged.
The results of preliminary studies with liquid anti-
venoms in which the cold chain was interrupted for short
time intervals also evidenced that stability was not signif-
icantly affected in these circumstances. This is a relevant
ﬁnding since failures in power supply often result in such
temporary interruptions in the cold chain. Moreover, the
effects of temporary freezing of antivenoms have to be also
considered and investigated, since this might occur during
storage and transportation. Alvaro Segura and Marı´a Her-
rera, from Instituto Clodomiro Picado, presented the results
of investigations aimed at developing new formulations for
liquid and lyophilized antivenoms, in order to improve
their stability. Promising results have been obtained with
the use of sorbitol in the stabilization of liquid preparations,
in order to store them at temperatures of around 25 C.
Overall, the results presented reinforce the need to perform
more detailed studies on the stability of antivenoms in the
region. The subject of cold chain was presented by Carmen
Silvera, from Brazil, who discussed all aspects related withthe correct storage and transportation of antivenoms and
the most common problems found in the region concern-
ing the maintenance of a cold chain. Due to a number of
difﬁculties for keeping a cold chain, especially in some rural
regions of Latin America, the need for a quality control of
the cold chain, including the regular monitoring of
temperature, was stressed.
3. Distribution of antivenoms
The situation of antivenom distribution to the hospitals
and other health facilities in the various countries in the
region was analyzed in detail.3.1. Brazil
The situation of acquisition and distribution of anti-
venoms inBrazilwaspresentedbyHuiWenFan andCarmen
Silvera. This country, which has a long tradition of
antivenom manufacture, created a National Program for
Self-Sufﬁciency in Immunobiologicals, which includes
antivenoms, in 1985. In addition, a National Program for the
Control of Accidents by Venomous Animals was established
in 1986. This program includes: (a) epidemiological
surveillance; (b) modernization of technology and infra-
structure for antivenom production; (c) standardization of
diagnostic and therapeutic parameters; (d) analysis of the
geographical distribution of venomous animals in the
country; and (e) introduction of permanent training
programs for health personnel. A total of 29,121 snakebite
cases were reported in Brazil in 2006. There are four public
laboratories that manufacture antivenoms, i.e. Instituto
Butantan, Fundaça˜o Ezequiel Dias (FUNED), Instituto Vital
Brazil, and Centro de Produça˜o e Pesquisa de Imunobiolo´-
gicos (CPPI). Antivenom production by these laboratories is
coordinatedwith theneedsof theMinistryofHealth and the
annual production is organized accordingly. A total of
424,763 antivenom ampoules were produced in 2007. The
acquisition process is centralized and antivenoms are
received by the National Center for the Distribution and
Storage of Immunobiologicals (CENADI). After the quality
control is performedby theNational Institute for theQuality
Control in Health (INCQS), the distribution of antivenoms is
authorized. Such distributionprocess is a decentralized one,
and is based on the antivenom needs of the various regions;
antivenoms are distributed to the State Secretaries of
Health, then to the Regional Ofﬁces of Health, then to the
Municipal Secretaries and ﬁnally to the Health Services.
The planning of antivenom distribution is based on the
following equation:
N ¼ ½ðx$yÞ þ ðaþ bÞ  d
where:
N¼ number of vials to be distributed.
x¼ number of snakebite cases.
y¼mean number of antivenom vials used per patient.
a¼ estimated underregistration of snakebite cases.
b¼ technical losses of antivenom (expired and/or
incorrectly stored or transported).
d¼ vials of antivenoms in stock in that region.
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a region or a health center, this formula is modiﬁed as
follows, in order to ensure an adequate antivenom stock:
N ¼ ½ðx$yÞ þ ðaþ bÞ$2
Evidently, an adequate epidemiological information is
a key element for the correct application of this equation
and, consequently, for a correct distribution strategy.
The information available allows the analysis of the
percentage of distributed antivenom ampoules which are
not used. This percentage is low in the case of Bothrops sp.
antivenom, but is higher for Lachesis sp. and Micrurus sp.
antivenoms; this is due to the higher incidence of cases by
Bothrops sp. In the case of the other two antivenoms,
despite the low incidence of these envenomations, anti-
venoms have to be distributed to all health posts where
these cases might occur and, consequently, the percentage
of antivenom ampoules not used by the time of expiry is
higher. The decision on which regions should receive
antivenoms is therefore based on the following parame-
ters: (a) epidemiological risk of envenomations; (b)
conditions for adequate storage and administration of
antivenoms; (c) existence of health posts and health staff;
(d) access to health centers in a relatively short time
interval; and (e) feasibility to perform medical references.
There are still regions in Brazil where the access to anti-
venoms is limited and where patients have to travel long
distances to receive antivenom treatment.
3.2. Argentina
The situationof antivenomacquisitionanddistributionby
the Ministry of Health in Argentina was presented by Chris-
tian Hertlein. The following number of snakebite cases were
reportedbetween2004and2007 inthevariousregionsof the
country: Northeast region: 624; Northwest region: 275;
Central region: 146; Cuyo region: 25; and Southern region: 8.
The Ministry of Health receives the antivenoms produced by
the public manufacturer, the National Institute for the
Production of Immunobiologicals – ANLIS, which produces
antivenoms against viperid and elapid venoms. During the
last years, this laboratory has provided theMinistry of Health
with between 5000 and 8000 vials of antivenomper year, an
amount that covers the total needs of the country for the
treatment of snakebite envenomations. Antivenoms are
provided to the section of Zoonoses of theMinistry of Health
(central level), which then distributes them to the jurisdic-
tional referents (intermediate level), and from there to the
health centers in the provinces (local level).
3.3. Paraguay
The situation of antivenomacquisition and distribution in
Paraguay was presented by Arnaldo Vera. Compulsory noti-
ﬁcationof snakebite envenomationswas introduced in2005;
this information is forwarded to the Coordination of Snake-
bite Accidents of theMinistry of Health and SocialWelfare. A
total number of 470 cases were reported in 2007, although it
is likely that thispathology isunderreported. There is no local
production of antivenoms; therefore they have to beimported either by direct purchase processes or by donation.
In 2008 a total of 1071 antivenom vials were distributed in
Paraguay; however, the total number of vials used is higher,
since there are decentralized acquisition processes at the
local levels. There is concern with the quality control of the
antivenoms being imported, since there is no local quality
control laboratory and no information has been gathered on
the preclinical efﬁcacy of imported antivenoms. There is
a need to prepare national reference venoms, to develop
endogenous capacity for quality control, and to establish
partnerships with laboratories in neighboring countries to
perform preclinical assessment of antivenoms.
3.4. Bolivia
The situation of antivenom acquisition and distribution
in Bolivia was presented byWilliams Velasco. An estimated
total number of 1000 snakebite cases occur per year,
although there is an evident underreport. There is a local
public laboratory that manufactures antivenoms, the
National Institute of Health Laboratories (INLASA), which
produced 1000 vials in 2007 and has produced 1300 vials in
2008. The country does not have a coordinated national
program for snakebite envenomations, and antivenom
distribution is deﬁcient, since it does not reach the health
centers in the regions where most snakebite cases occur.
3.5. Ecuador
The situation of antivenomacquisition and distribution in
Ecuador was presented by Leonor Sua´rez. Epidemiological
surveys by the Ministry of Health indicate that, during 2007,
a total number of 1470 snakebite cases occurred in this
country: 210 in the Sierra region, 765 in the Coast region, and
495 in the Western region. A total number of 2673 vials of
antivenom were used in 2007. There is a national public
manufacturing laboratory, the National Institute of Health
‘Leopoldo Izquieta Pe´rez’. Antivenoms are acquired by the
Ministry of Health for distribution in the country. This insti-
tute also harbors the laboratory of the National Control for
Biologicals, in charge of the quality control of all antivenoms
used in the country. In addition to the locally manufactured
products, antivenoms imported from Brazil, Mexico,
Colombia and Costa Rica have been used in emergency situ-
ations. Donations of antivenoms are sometimes received.
After the process of quality control, antivenoms are sent to
the National Bank of Vaccines, in Quito, for storage. Distri-
bution is organized on the basis of the needs of each region,
through the Regional Subsecretaries, which distribute anti-
venoms to the provinces, areas and operative units.
3.6. Colombia
The situation of antivenomacquisition and distribution in
Colombia was presented by Teresa Sarmiento. Compulsory
notiﬁcation of snakebite envenomation was introduced in
2004; a total number of 2737 snakebite cases were reported
in 2007. A public institution, the National Institute of Health
(INS), and a private laboratory manufacture antivenoms in
Colombia. A regulatory entity, the National Institute for the
Surveillance ofMedicines and Food (INVIMA), authorizes the
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of antivenoms on a regular basis. Antivenom distribution
occurs by two main mechanisms: (a) the health insurance
companies, responsible of guaranteeing the provision of
antivenoms to their clients according to the epidemiological
proﬁle of the various regions in the country, and (b) the
Ministry of Social Protection, which has antivenom stocks to
satisfy antivenom needs in situations of emergency and
natural disasters. Likewise, the Ministry purchases anti-
venoms that are not produced in the country, such as anti-
Micrurus antivenoms.
3.7. Panama
The situation of antivenom acquisition and distribution
in Panama was presented by Nereida Quintero, from Caja
del Seguro Social, and Dio´genes Castillo, from the Ministry
of Health. These two institutions have hospitals where
snakebite envenomations are treated. Panama presents
the highest incidence of snakebite cases in the Americas
(40–65 cases per 100,000 population per year), with an
estimated total number of 1300–1800 cases per year.
Compulsory notiﬁcation of snakebite envenomation was
established in 2001. Polyvalent (Crotaline) and anti-coral
(Elapid) antivenoms are regularly purchased, according to
the needs of the health system, through well-established
acquisition protocols. In the last decade, all antivenoms
required in the country have been provided by Instituto
Clodomiro Picado (Costa Rica). During 2007 the Caja del
Seguro Social acquired 9600 vials of polyvalent antivenom
and 125 vials of anti-coral antivenom, whereas in 2008 the
Ministry of Health acquired 12,000 vials of polyvalent
antivenom and 400 vials of anti-coral antivenom. Once
purchased, antivenoms are received by the institutionmain
stockroom and, after quality control is performed, the
products are distributed to hospitals and health centers of
the various regions in the country through a well-
controlled cold chain. A system of pharmacological
surveillance of antivenoms is being organized in Panama.
3.8. Costa Rica
The situation of antivenom acquisition and distribution
in Costa Rica was presented by Desire´e Sa´enz and Iliana
Chavarrı´a. Compulsory notiﬁcation of snakebite enveno-
mationswas introduced inCostaRica in1997. Thenumberof
snakebite cases in this country is around 600 per year, all of
which are attended in hospitals, clinics and other health
centers of Caja Costarricense del Seguro Social (CCSS).
Antivenoms are included in the ofﬁcial list of medicines of
CCSS. A public laboratory, Instituto Clodomiro Picado
(University of Costa Rica) provides all the antivenoms
needed in the country, which amount approximately to
15,000 vials of polyvalent (Crotaline) and 2500 vials of anti-
coral (Elapid) antivenom. After the purchase of antivenoms,
the quality control laboratory of CCSS certiﬁes antivenom
quality. Antivenoms are then distributed, on the basis of
regional needs, to three different levels: (a) National
hospitals (level III); (b) major clinics and peripheral hospi-
tals (level II); and (c) primary health careunits (EBAIS) (level
I). An institutional protocol for the use of antivenom and thetreatment of snakebite cases was recently approved and
distributed (Caja Costarricense del Seguro Social, 2008).
3.9. Nicaragua
The situation of antivenom acquisition and distribution
in Nicaragua was presented by Luz Marina Lozano. A total
of 636 snakebite cases were reported in this country in
2007. This pathology is of compulsory notiﬁcation. Anti-
venoms are imported and acquired by the Ministry of
Health and are included in the Basic List of Medicines in
Nicaragua. During the last decade, all antivenoms used in
this country have been provided by Instituto Clodomiro
Picado (Costa Rica). The Ministry of Health acquired 9000
vials of polyvalent (Crotaline) and 2000 vials of anti-coral
(Elapid) antivenoms in 2008. According to the epidemio-
logical patterns and the needs of each region, antivenoms
are distributed to three basic types of health units: (a)
National reference hospitals and regional hospitals; (b)
health centers with beds; (c) primary health care units at
local levels that have physicians. There are problems with
the accessibility of antivenoms in regions where the cold
chain is deﬁcient or where the health units are located far
from the sites where snakebites occur.
4. The use of Geographic Information System (GIS) in
antivenom distribution
The need to have tools to develop more rigorous and
effective national policies of antivenom distribution was
emphasized. Gerardo Leynaud presented the experience at
the province of Co´rdoba, Argentina, with the use of a free
access GIS software, developed by the Pan American Health
Organization (PAHO) for research in epidemiology and
public health, named SIGEpi (http://ais.paho.org/sigepi/
index.asp?xml ¼ sigepi/index.htm), which can be used for
the determination of high-risk areas of snakebite enveno-
mation. These areas are selected on the basis of an inte-
grated analysis that includes distribution of venomous
snakes, epidemiology of envenomations, access to health
centers, quality of the road systems and coverage of the
cold chain. The applications of this software were dis-
cussed, and the need to undertake cooperative efforts
between health authorities and research groups of the
various countries to implement its use was stressed.
5. The correct use of antivenoms: experiences with
the training of health staff in snakebite envenomation
treatment
The correct use of antivenoms constitutes, togetherwith
an adequate distribution system, an essential component in
the overall control of snakebite envenomations (WHO,
2007). The training of medical, pharmacy and nursing staff
in the basic aspects of diagnosis, prescription, and admin-
istration of antivenoms, together with the management of
adverse reactions to these immunobiologicals, is of utmost
importance. This training has to be performed through
a variety of activities at the university level, as well as by
permanent educational programs at the health centers,
particularly in regions with high incidence of these
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professionals carried out in Brazil, Paraguay, Costa Rica and
Panama were presented by Hui Wen Fan, Arnaldo Vera,
Alexandra Rucavado and Hildaura Acosta, respectively.
Diverse trainingmethodologies have been used, such as the
introduction of this subject in university courses, the
development of permanent programs taught in health
centers, the publication of national guidelines for treat-
ment of envenomations, the publication of papers in
scientiﬁc journals, and the development of materials in
posters, CDs and other media (see for example Ministe´rio
de Sau´de de Brasil, 1998; Ministerio de Salud Pu´blica y
Bienestar Social de Paraguay, 2008; Caja Costarricense del
Seguro Social, 2008).
Despite the successes achieved by many of these
programs, a critical appraisal of these activities was per-
formed on the basis of the mistakes occurring in the treat-
ment of these envenomations. These include a frequent lack
of knowledge on the clinical presentation of these enveno-
mations, on the selection of the type of antivenom to be
used, on the decision on whether a patient requires anti-
venom or not, on the volume of antivenom required
according to the severity of the case, and on the prompt
treatment of the most common complications in these
envenomations. This situation demands renewed efforts at
improving the training programs, both in termsof preparing
new teaching materials, the basic structure and method-
ology of the activities, and the design of strategies to reach
the health staff of the regions of highest incidence of
snakebites, often located in remote rural areas. The need to
develop national and regional guidelines for the diagnosis
and treatment of snakebite envenomations was empha-
sized. In addition, the participants discussed the urgent
need to develop methodologies aimed at the evaluation of
the effectiveness of the various types of training activities.
6. Conclusions and recommendations
(1) There is a large heterogeneity in Latin America in the
consolidation of strategies aimed at confronting the
problem of snakebite envenomation. It is necessary to
strengthen the cooperative links between countries in
order to improve the regional production, quality
control and distribution of antivenoms, as well as the
training programs to health staff in the region.
(2) Antivenommanufacturers should undertake the study
of the stability of their antivenoms and the develop-
ment of novel formulations aimed at improving this
stability.
(3) It is recommended that all countries develop their
endogenous capacity to prepare national references of
the most important venoms and to perform quality
control of antivenoms being produced in the country
or being imported. The development of these capac-
ities demands regional cooperation and training
programs. The meticulous preclinical assessment of
the efﬁcacy of antivenoms produced and used in the
region is an important task.
(4) Due to problems of antivenom acquisition in various
countries, it is recommended that rapid and effective
procurement processes should be developed in theregion. The active participation of PAHO in these
processes in situations of emergency is very important.
(5) There is an urgent need to perform research in the
antivenom distribution systems in Latin America, in
order to gain a precise understanding on the main
problems associated with this issue and, consequently,
to develop more effective distribution strategies.
(6) It is necessary to improve the information systems on
the epidemiology of snakebite envenomations in the
region. This information is essential for the design of
effective distribution policies and training programs.
(7) The use of GIS methods in the study of snakebite
envenomation should be encouraged, as a tool to gain
more precise and objective information of the most
vulnerable areas.
(8) There is a need to develop methods for the qualitative
and quantitative assessment of antivenom usage in the
region. The quality of the medical attention provided
to snakebitten patients has to be properly evaluated in
order to detect deﬁciencies and to design more effec-
tive training programs.
(9) The development and strengthening of permanent
training programs to health staff is an essential
component in an integrated strategy to confront
snakebite envenomation in the region. It is necessary
to develop tools to assess the efﬁcacy of the training
activities developed.
(10) The preparation of national and regional guidelines for
the diagnosis and treatment of snakebite envenoma-
tions, including the correct use of antivenoms, should
be actively encouraged in the region.
(11) Training programs, aimed at health and administrative
staff, on the correct storage, distribution and use of
antivenoms, including themaintenance of an adequate
cold chain, should be developed.
(12) It is necessary to organize national pharmacological
surveillance programs to monitor the therapeutic
performance of antivenoms, both in terms of efﬁcacy
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